Trial · NCT02623439
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
NCT02623439, Phase 2, Terminated, University of California, San Diego; results first posted 2025-11-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies. Trials, record NCT02623439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02623439
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
- NCT number
- NCT02623439
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Hematologic Malignancies
- Interventions
- Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
- First posted
- 2015-12-07
- Last updated
- 2025-11-10
- Results first posted
- 2025-11-10
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Day 180 | 180 days after transplantation |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | Day 180 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | cyclophosphamide post BMT | 3 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | cyclophosphamide post BMT | 10 | |
| Overall Study | COMPLETED | cyclophosphamide post BMT | 8 | |
| Overall Study | NOT COMPLETED | cyclophosphamide post BMT | 2 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Human herpesvirus 6 (HHV-6) | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | Enterococcus Faecalis UTI | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | BC (+) Rothia mucilaginosa septicemia | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | CMV | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | acute GVHD | Immune system disorders | cyclophosphamide post BMT | 2 | 8 | 3 |
| other | aspergillosis | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | stenotrophomomas pneumonia | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | Cytokine storm | Blood and lymphatic system disorders | cyclophosphamide post BMT | 2 | 8 | 2 |
| other | vancomycin-resistant enterococcus (VRE) | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | pulmonary infiltrates | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | cyclophosphamide post BMT | 5 | 8 |
| Total, other adverse events | cyclophosphamide post BMT | 8 | 8 |
| Total, serious adverse events | cyclophosphamide post BMT | 5 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02623439
GET https://conductscience.org/api/trials/v1/NCT02623439/registered